Dual-mRNA Delivery Using Tumor Cell Lysate-Based Multifunctional Nanoparticles as an Efficient Colon Cancer Immunogene Therapy
Kaiyu Wang,Yan Gao,Shan Wu,Jin Zhang,Manfang Zhu,Xiayu Chen,Xizi Fu,Xingmei Duan,Ke Men
DOI: https://doi.org/10.2147/ijn.s452548
IF: 7.033
2024-05-28
International Journal of Nanomedicine
Abstract:Kaiyu Wang, 1, &ast Yan Gao, 1, &ast Shan Wu, 1, &ast Jin Zhang, 1 Manfang Zhu, 2 Xiayu Chen, 1 Xizi Fu, 1 Xingmei Duan, 2 Ke Men 1 1 State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, People's Republic of China; 2 Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xingmei Duan, Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, People's Republic of China, Email Ke Men, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital of Sichuan University, Chengdu, 610041, People's Republic of China, Email Background: Messenger RNA (mRNA)-based immunogene therapy holds significant promise as an emerging tumor therapy approach. However, the delivery efficiency of existing mRNA methods and their effectiveness in stimulating anti-tumor immune responses require further enhancement. Tumor cell lysates containing tumor-specific antigens and biomarkers can trigger a stronger immune response to tumors. In addition, strategies involving multiple gene therapies offer potential optimization paths for tumor gene treatments. Methods: Based on the previously developed ideal mRNA delivery system called DOTAP-mPEG-PCL (DMP), which was formed through the self-assembly of 1.2-dioleoyl-3-trimethylammonium-propane (DOTAP) and methoxypoly (ethylene glycol)-b-poly (&epsiv-caprolactone) (mPEG-PCL), we introduced a fused cell-penetrating peptide (fCPP) into the framework and encapsulated tumor cell lysates to form a novel nanovector, termed CLSV system (CLS: CT26 tumor cell lysate, V: nanovector). This system served a dual purpose of facilitating the delivery of two mRNAs and enhancing tumor immunogene therapy through tumor cell lysates. Results: The synthesized CLSV system had an average size of 241.17 nm and a potential of 39.53 mV. The CLSV system could not only encapsulate tumor cell lysates, but also deliver two mRNAs to tumor cells simultaneously, with a transfection efficiency of up to 60%. The CLSV system effectively activated the immune system such as dendritic cells to mature and activate, leading to an anti-tumor immune response. By loading Bim-encoded mRNA and IL-23A-encoded mRNA, CLSV/Bim and CLSV/IL-23A complexes were formed, respectively, to further induce apoptosis and anti-tumor immunity. The prepared CLSV/dual-mRNA complex showed significant anti-cancer effects in multiple CT26 mouse models. Conclusion: Our results suggest that the prepared CLSV system is an ideal delivery system for dual-mRNA immunogene therapy. Keywords: mRNA gene therapy, dual-mRNA delivery, tumor cell lysates, Bim and IL-23A mRNAs, immune response Cancer has become a significant public health concern worldwide, with increasing mortality rates in many countries. 1 Traditional treatment approaches include surgery, radiation therapy, hormone therapy, chemotherapy, and targeted therapy (including immunotherapy), among others. 2 Among the promising novel strategies, messenger RNA (mRNA) gene therapy has emerged as a cutting-edge approach, involving utilizing synthetic mRNA molecules to convey genetic instructions to cells. 3,4 On the basis of its non-integrative, rapid expression, and biodegradable characteristics, the potential of mRNA gene therapy for disease treatment has been widely acknowledged. 5 For instance, during the 2019 coronavirus disease pandemic, two mRNA vaccines (BNT162b2 and mRNA-1273) were the first to receive emergency approval. 6,7 Because cancer is a complex disease associated with multiple inherited genes, single-gene targeted therapy can have limited therapeutic effects; 8 therefore, exploring the potential of dual-mRNA gene therapy has the potential to transform treatment strategies and further improve the therapeutic effect. The dual-mRNA gene therapy approach, which allows simultaneous delivery of two functional mRNAs, has many advantages in cancer treatment. This approach can express proteins encoded by two therapeutic genes, thereby exerting two or more anti-tumor therapeutic strategies. These two mRNAs can cooperate to achieve comple -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology